# 4D pharma plc Announces publication of data highlighting immuno-stimulatory properties of MRx0518

- Link: https://www.directorstalkinterviews.com/4d-pharma-plc-announces-publication-of-data-highlighting-immuno-stimulatory-properties-of-mrx0518/412765764
- Published: 2019-01-29T07:08:27+00:00
- Author: Giles Arbor

**4D pharma plc** (LON: DDDD), a pharmaceutical company leading the development 
of Live Biotherapeutics, today announced the publication of a paper outlining the
mechanism and strong immuno-stimulatory effects of MRx0518.

The paper ‘The flagellin of candidate live biotherapeutic Enterococcus gallinarum
MRx0518 is a potent immunostimulant’ (Lauté-Caly et al) is published in the Nature
Publishing Group journal Scientific Reports.

4D researchers demonstrated that MRx0518 stimulates both the innate and adaptive
immune systems and identified the bacterial flagellin (a specific component of the
MRx0518 bacterium) that interacts with the host TLR5 receptors as a mediator of 
this process. The TLR5 pathway is known to be associated with the body’s response
to cancer.

> **Dr Alex Stevenson, 4D pharma Chief Scientific Officer, commented:**
> “This publication exemplifies our commitment to conducting leading microbiome 
> research and further highlights the importance of a strain-level understanding
> of function and mechanism in selecting live biotherapeutic candidates for clinical
> development.”

4D is conducting a number of clinical trials with MRx0518 across a range of settings
in 2019. The first of which, a combination study with Keytruda® in collaboration
with Merck & Co., Inc., Kenilworth, NJ., USA, and conducted at MD Anderson Cancer
Centre, is open for recruitment.

Please find a copy of the paper here: [www.nature.com/articles/s41598-018-36926-8](http://www.nature.com/articles/s41598-018-36926-8)

Share on: